Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (Efavirenz)

被引:25
作者
Gao, J. Zh. [1 ]
Hussain, M. A.
Motheram, R.
Gray, D. A. B.
Benedek, I. H.
Fiske, W. D.
Doll, W. J.
Sandefer, E.
Page, R. C.
Digenis, G. A.
机构
[1] Bristol Myers Squibb Co, Biopharmaceut R&D, New Brunswick, NJ 08903 USA
[2] Med Co, Parsippany, NJ 07054 USA
[3] Endo Pharmaceut, Chadds Ford, PA 19317 USA
[4] Scintipharma Inc, Lexington, KY 40503 USA
[5] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA
关键词
in vitro and in vivo disintegration and dissolution; gamma scintigraphy; gastrointestinal transit; pharmacokinetics; bioavailability;
D O I
10.1002/jps.20962
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble, highly permeable, micronized drug (efavirenz) was investigated. The tablets and capsule, prepared with samarium oxide and neutron activated to produce radioactive samarium-153, were evaluated for their in vivo disintegration and gastrointestinal (GI) transit in healthy subjects under fasted condition. Scintigraphic images were acquired to coincide with blood sampling times to assess the plasma concentration-time profile in relation to in vivo disintegration and GI transit. The mean gastric emptying times were approximately the same for all three formulations. Although in vivo dosage form disintegration was faster for Tablet A as compared to Tablet B and was similar between Tablet A and the capsule, Tablet A showed a slower rate and extent of drug absorption than Tablet B and the capsule. The results of this study eliminated the initial hypothesis that the difference in in vivo performance between the two tablet formulations is due to a different rate of in vivo disintegration and suggest that for this drug the in vivo dissolution rate of the drug from its disintegrated dosage form was a more important factor affecting the rate and extent of drug absorption. (C) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:2970 / 2977
页数:8
相关论文
共 13 条
[1]   Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant .2. The choice of super disintegrants and effect of granulation [J].
Bolhuis, GK ;
Zuurman, K ;
teWierik, GHP .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 5 (02) :63-69
[2]  
DIGENIS GA, 1991, CRIT REV THER DRUG, V7, P309
[3]   IMAGING AND BEHAVIOR OF SOLID ORAL DOSAGE FORMS INVIVO [J].
FELL, JT ;
DIGENIS, GA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1984, 22 (01) :1-15
[4]   Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs [J].
Galia, E ;
Nicolaides, E ;
Hörter, D ;
Löbenberg, R ;
Reppas, C ;
Dressman, JB .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :698-705
[5]   Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract [J].
Horter, D ;
Dressman, JB .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 25 (01) :3-14
[6]   Evaluation of the in vivo disintegration of solid dosage forms of a bile acid sequestrant in dogs using γ-scintigraphy and correlation to in vitro disintegration [J].
Hussain, MA ;
Chang, RK ;
Sandefer, E ;
Page, RC ;
Digenis, GA .
PHARMACEUTICAL RESEARCH, 2003, 20 (03) :460-464
[7]   ESTIMATION OF AGITATION INTENSITY IN THE GI TRACT IN HUMANS AND DOGS BASED ON IN-VITRO IN-VIVO CORRELATION [J].
KATORI, N ;
AOYAGI, N ;
TERAO, T .
PHARMACEUTICAL RESEARCH, 1995, 12 (02) :237-243
[8]   ON THE INTESTINAL TRANSIT OF A SINGLE NON-DISINTEGRATING OBJECT [J].
KAUS, LC ;
FELL, JT ;
SHARMA, H ;
TAYLOR, DC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1984, 20 (03) :315-323
[9]   The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir) [J].
Kenyon, CJ ;
Brown, F ;
McClelland, GR ;
Wilding, IR .
PHARMACEUTICAL RESEARCH, 1998, 15 (03) :417-422
[10]   In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy [J].
Marathe, PH ;
Sandefer, EP ;
Kollia, GE ;
Greene, DS ;
Barbhaiya, RH ;
Lipper, RA ;
Page, RC ;
Doll, WJ ;
Ryo, UY ;
Digenis, GA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1998, 26 (01) :1-20